Natixis’s Alaunos Therapeutics TCRT Stock Holding History

Natixis’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-109	Closed	-$100K	–	1157
2017 Q3	$100K	Buy	+109	New	+$96.8K	﹤0.01%	1186

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Natixis's TCRT Position: Q4 2017 in Review

Natixis sold out of Alaunos Therapeutics (TCRT) in Q4 2017, closing a stake of 109 shares — an estimated $100K sold.

Natixis first reported a position in TCRT in Q3 2017 and held it in 1 quarter. The position peaked at $100K in Q3 2017. 128 funds tracked by Wall St. Rank hold TCRT as of Q4 2017.

Natixis reported no remaining Alaunos Therapeutics position as of Q4 2017 after selling out during the quarter.
Natixis sold 109 Alaunos Therapeutics shares in Q4 2017, an estimated $100K.
Natixis first reported a position in Alaunos Therapeutics in Q3 2017 and held it in 1 quarter.
Natixis's Alaunos Therapeutics position peaked at $100K in Q3 2017.
128 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2017.

Based on Natixis's 13F filing for Q4 2017, filed 14 Feb 2018.